# Cardiometabolic Devices Accuracy Study

Study · id `cardio:ct-nct05257564` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05257564](<https://clinicaltrials.gov/study/NCT05257564>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05257564

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease; Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 359 participants.

## Technical summary

Registry record NCT05257564. Allocation not applicable; no masking; primary purpose diagnostic. Start 2022-02-14 (actual); primary completion 2022-05-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 359 participants (enrolled count; ClinicalTrials.gov record NCT05257564, source copy `cardio:ctgov-nct05257564-2024-03-20`, retrieved 2026-10-26)
- Started: 2022-02-14 (actual) (ClinicalTrials.gov record NCT05257564, source copy `cardio:ctgov-nct05257564-2024-03-20`, retrieved 2026-10-26)
- Primary completion: 2022-05-29 (actual) (ClinicalTrials.gov record NCT05257564, source copy `cardio:ctgov-nct05257564-2024-03-20`, retrieved 2026-10-26)
- Completion: 2022-06-30 (actual) (ClinicalTrials.gov record NCT05257564, source copy `cardio:ctgov-nct05257564-2024-03-20`, retrieved 2026-10-26)
- Countries: Nepal (ClinicalTrials.gov record NCT05257564, source copy `cardio:ctgov-nct05257564-2024-03-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05257564-2024-03-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cardiometabolic Devices Accuracy Study
- Condition: Diabetes Mellitus
- Condition: Chronic Kidney Diseases
- Condition: Hyperlipidemias
- Intervention (Device): Determine the accuracy of quantitative measurements of GLU, HbA1c,CHOL and CRE with POC devices compared to a laboratory reference method (Roche)
- Lead sponsor: Foundation for Innovative New Diagnostics, Switzerland
- Lead sponsor class: OTHER
- Collaborator: University Hospital, Geneva
- Collaborator class: OTHER
- Collaborator: B.P. Koirala Institute of Health Sciences
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: University Hospital, Geneva (`cardio:org-university-hospital-geneva`)

## Provenance

Content hash: 9eb0a0524a529344d5a1eb36760e4258ae207c23934149eeb05e098664594a22
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
